Alpha-1 Antitrypsin Deficiency

Methods and Protocols

Edited by

Florie Borel
Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA

Christian Mueller
Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA;
Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA

Humana Press
Preface

Why Did We Write This Book?

The book was triggered by the expansion in the field of alpha-1 antitrypsin (AAT) research. While by no means exhaustive, this book is meant to provide the essential protocols to laboratories ranging from new scientists in the field to more established alpha-one researchers. The aim of this book is to present a solid background by experts in their respective subfield of AAT research as well as state-of-the-art methods that are relevant to the audience, for both clinical and the bench researchers.

Who Is This Book For?

The intended audience of this book is researchers, students, and clinician-scientists interested in AAT deficiency, as well as clinicians in particular those in the fields of pulmonology and hepatology.

What Is in the Book?

This volume of the Methods in Molecular Biology series provides a collection of protocols. The book opens with reviews on the pathophysiology of the liver and lungs. Subsequently, protocols are organized in three parts: Part I is dedicated to patient-oriented research, Part II to animal models, and Part III to in vitro work. The book concludes with reviews from experts in the various fields relating to AAT translational research who share their vision of current and/or future therapeutics.

Worcester, MA, USA

Flore Borel
Christian Mueller
Acknowledgments

This book is the result of a long effort from many parties, and we would like to thank the publisher for entrusting us with this task, as well as to convey our appreciation to all our authors for their time and effort on this endeavor. We would like to acknowledge the wonderful alpha-1 patient community who remains a constant source of inspiration to many AAT labs around the world. We would like to dedicate this work to John and Fred Walsh who both have already accomplished so much for the field by increasing awareness and research for patients with alpha-1 antitrypsin deficiency and who are very dear to all the members of the Mueller Lab. Finally, we hope that this volume may find its place in many labs and contribute to the development of new therapeutics for alpha-1 patients.
# Contents

Preface ................................................................. v  
Acknowledgments ...................................................... vii  
Contributors ............................................................ xi

1 Pathophysiology of Alpha-1 Antitrypsin Deficiency Liver Disease ............. 1  
Jeffrey H. Teckman and Keith S. Blomenkamp

2 Pathophysiology of Alpha-1 Antitrypsin Lung Disease .......................... 9  
Michael Kalfopoulos, Kaitlyn Wetmore, and Mai K. ElMallah

3 Measuring and Interpreting Serum AAT Concentration ........................ 21  
Leslie J. Donato, Melissa R. Snyder, and Dina N. Greene

4 AAT Phenotype Identification by Isoelectric Focusing ......................... 33  
Dina N. Greene, M.C. Elliott-Jelf, and David G. Grenache

5 Laboratory Diagnosis by Genotyping ........................................... 45  
Irene Belmonte, Luciana Montoto, and Francisco Rodríguez-Frias

6 Genotyping Protocol for the Alpha-1 Antitrypsin (PiZ) Mouse Model ........ 61  
Alisba M. Gruntman

7 Elastase-Induced Lung Emphysema Models in Mice ............................ 67  
Béla Suki, Erzsöbet Bartolák-Suki, and Patricia R.M. Rocco

8 Assessing Structure–Function Relations in Mice Using the Forced  
Oscillation Technique and Quantitative Histology ................................ 77  
Harikrishnan Parameswaran and Béla Suki

9 Practical Methods for Assessing Emphysema Severity Based  
on Estimation of Linear Mean Intercept (Lm) in the Context  
of Animal Models of Alpha-1 Antitrypsin Deficiency .......................... 93  
Airiel M. Davis, Kristen E. Thane, and Andrew M. Hoffman

10 Design, Cloning, and In Vitro Screening of Artificial miRNAs  
to Silence Alpha-1 Antitrypsin ............................................... 107  
Florie Borel and Christian Mueller

11 Methods to Identify and Characterize siRNAs Targeting Serpin A1  
In Vitro and In Vivo Using RNA Interference .................................... 115  
Stuart Milstein, Kun Qian, Linying Zhang, and Alfica Sehgal

12 Knockdown of Z Mutant Alpha-1 Antitrypsin In Vivo  
Using Modified DNA Antisense Oligonucleotides ............................ 127  
Mariam Aghajan, Shuling Guo, and Brett P. Monia

13 Immunohistochemistry Staining for Human Alpha-1 Antitrypsin .......... 139  
Dongtao A. Fu and Martha Campbell-Thompson

14 Periodic Acid-Schiff Staining with Diastase .................................. 145  
Dongtao A. Fu and Martha Campbell-Thompson

15 Protocol for Directed Differentiation of Human Induced Pluripotent  
Stem Cells (iPSCs) to a Hepatic Lineage ...................................... 151  
Joseph E. Kaserman and Andrew A. Wilson
16 Isolation of Kupffer Cells and Hepatocytes from a Single Mouse Liver ........ 161
Marcela Aparicio-Vergara, Michaela Tencerova, Cecilia Morgantini,
Emelie Barreby, and Myriam Aouadi

17 Alpha-1 Antitrypsin Transcytosis and Secretion .................................. 173
Angelia D. Lockett

18 Measuring the Effect of Histone Deacetylase Inhibitors (HDACi)
on the Secretion and Activity of Alpha-1 Antitrypsin .......................... 185
Chao Wang, Marion Bouchebacelb, and William E. Balch

19 Expression and Purification of Active Recombinant Human
Alpha-1 Antitrypsin (AAT) from Escherichia coli ................................. 195
Beena Krishnan, Lizbeth Hedstrom, Daniel N. Hebert,
Lila M. Gierasch, and Anne Gershenson

20 Quantification of Total Human Alpha-1 Antitrypsin by Sandwich ELISA .... 211
Qiushi Tang, Alisha M. Gruntman, and Terence R. Flotte

21 Quantification of Murine AAT by Direct ELISA .................................. 217
Andrew Cox and Christian Mueller

22 Quantification of Z-AAT by a Z-Specific “Sandwich” ELISA ................. 223
Florie Borel, Qiushi Tang, and Christian Mueller

23 Semiquantitation of Monomer and Polymer Alpha-1 Antitrypsin
by Centrifugal Separation and Assay by Western Blot of Soluble
and Insoluble Components .................................................. 227
Keith S. Blomenkamp and Jeffrey H. Teckman

24 Electrophoresis- and FRET-Based Measures of Serpin Polymerization ..... 235
Sarah V. Faull, Anwen E. Brown, Imran Haq, and James A. Irving

25 Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy .................. 249
Michael Campos and Jorge Lascano

26 Therapeutic Options in Alpha-1 Antitrypsin Deficiency:
Liver Transplantation .................................................................. 263
Nedim Hadzic

27 Therapeutics: Gene Therapy for Alpha-1 Antitrypsin Deficiency .......... 267
Alisha M. Gruntman and Terence R. Flotte

Index .................................................................................... 277
Contributors

MARIAM AGHAJAN • Department of Antisense Drug Discovery, IONIS Pharmaceuticals, Carlsbad, CA, USA

MYRIAM AOUADI • Department of Medicine, Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Center, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden

MARCELA APARICIO-VERGARA • Department of Medicine, Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Center, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden

WILLIAM E. BALCH • Department of Molecular Medicine, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA

EMELIE BARREBY • Department of Medicine, Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Center, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden

ERZSE´ BET BARTOLA´ K-SUKI • Department of Biomedical Engineering, Boston University, Boston, MA, USA

IRENE BELMONTE • Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; Vall d’Hebron Institut de Reserca (VHIR), Barcelona, Spain

KEITH S. BLOMENKAMP • Department of Pediatrics, Saint Louis University, Saint Louis, MO, USA

FLORIE BOREL • Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA

MARION BOUCHECAREILH • Institut de Biochimie et Génétique Cellulaires, CNRS UMR 5095, Université de Bordeaux, Bordeaux, France

ANWEN E. BROWN • UCL Respiratory, University College London, London, UK

MARTHA CAMPBELL-THOMPSON • Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA

MICHAEL CAMPOS • Division of Pulmonary, Sleep and Critical Care Medicine, Miller School of Medicine, University of Miami, Miami, FL, USA

ANDREW COX • Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA

AIRIEL M. DAVIS • Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA, USA

LESLE J. DONATO • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

M. C. ELLIOTT-JELF • ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA

MAI K. ELMALLAH • Division of Pulmonary Medicine, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA; Department of Gene Therapy, University of Massachusetts Medical School, Worcester, MA, USA

SARAH V. FAULL • Division of Structural Biology, The Institute of Cancer Research, London, UK
CECILIA MORGANTINI • Department of Medicine, Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Center, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden

CHRISTIAN MUELLER • Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA; Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA

HARIKRISHNAN PARAMESWARAN • Northeastern University College of Bioengineering, Boston, MA, USA

KUN QIAN • Alnylam Pharmaceuticals, Cambridge, MA, USA

PATRICIA R.M. ROCCO • Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

FRANCISCO RODRÍGUEZ-FRÍAS • Liver Pathology Unit, Departments of Biochemistry and Microbiology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain; CIBER de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto Nacional de Salud Carlos III, Madrid, Spain

ALFICA SEHGAL • Alnylam Pharmaceuticals, Cambridge, MA, USA

MELISSA R. SNYDER • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

BÉLA SUKI • Department of Biomedical Engineering, Boston University, Boston, MA, USA

QIUSHI TANG • Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA; Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA

JEFFREY H. TECKMAN • Department of Pediatrics, Saint Louis University School of Medicine, Saint Louis, MO, USA; Department Biochemistry and Molecular Biology, Saint Louis University School of Medicine, Saint Louis, MO, USA; Department of Pediatric Gastroenterology and Hepatology, Cardinal Glennon’s Medical Center, Saint Louis, MO, USA

MICHAELA TENCEROVA • KMEB, Molecular Endocrinology, University of Southern Denmark, Odense, Denmark

KRISTEN E. THANE • Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA, USA

CHAO WANG • Department of Molecular Medicine, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA

KAITLYN WETMORE • Division of Pulmonary Medicine, Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA, USA; Department of Gene Therapy, University of Massachusetts Medical School, Worcester, MA, USA

ANDREW A. WILSON • Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center, Boston, MA, USA

LINYING ZHANG • Alnylam Pharmaceuticals, Cambridge, MA, USA